Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide

Archives of Ophthalmology

Volumn 122, Issue 8, 2004, Pages 1179-1184

  Keino, Hiroshi ^a   Kezuka, Takeshi ^a   Takeuchi, Masaru ^a   Yamakawa, Naoyuki ^a   Hattori, Takaaki ^a   Usui, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERPHOTORECEPTOR RETINOID BINDING PROTEIN; SODIUM CHLORIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UVEITIS; UVEORETINITIS;

ANIMALS; AUTOIMMUNE DISEASES; EYE PROTEINS; FEMALE; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C57BL; PEPTIDES; PERITONEAL CAVITY; RETINITIS; RETINOL-BINDING PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; T-LYMPHOCYTES; UVEITIS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 3543123032     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.8.1179     Document Type: Article

References (18)

1. Streilein JW. Immune privilege as a result of local tissue barriers and immunosuppressive microenvironments. Curr Opin Immunol. 1993;5:428-432.
2. Streilein JW, Cousins SW. Aqueous humor factors and their effect on the immune response in the anterior chamber. Curr Eye Res. 1990;9(suppl):175-182.
3. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32:33-43.
4. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone asa potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11:1199-1206.
5. Taylor AW, Yee DG, Streilein JW. Suppression of nitric oxide generated by inflammatory microphage by calcitonin gene-related peptide in aqueous humor. Invest Ophthalmol Vis Sci. 1998;39:1372-1378.
6. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol. 1994;153:1080-1086.
7. Pozo D, Delgado M, Martinez JM, et al. Immunobiology of vasoactive intestinal peptide (VIP) [published correction appears in Immunol Today. 2000;21:191]. Immunol Today. 2000;21:7-11.
8. Pozo D, Delgado M, Martinez JM, et al. Immunobiology of vasoactive intestinal peptide (VIP) [published correction appears in Immunol Today. 2000;21:191]. Immunol Today. 2000;21:7-11.
9. Delgado M, Laceta J, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 response by up-regulating B7.2 expression. J Immunol. 1999;163:3629-3635.
10. Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci. 2000;41:127-131.
11. Sun B, Rizzo LV, Sun SH, et al. Genetic susceptibility to experimental autoimmune uveitis involves more than a predisposition to generate a T helper-1-like or a T helper-2-like response. J Immunol. 1997;159:1004-1011.
12. Chan CC, Caspi RR, Ni M, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun. 1990;3:247-255.
13. Goetzl E, Voice JK, Shen S, et al. Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A. 2001;98: 13854-13859.
14. Hara Y, Caspi RR, Wiggert B, Dorf M, Streilein JW. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye [published correction appears in J Immunol. 1992;149:4116]. J Immunol. 1992;149:1531-1538.
15. Hara Y, Caspi RR, Wiggert B, Dorf M, Streilein JW. Analysis of an in vitro-generated signal that induces systemic immune deviation similar to that elicited by antigen injected into the anterior chamber of the eye [published correction appears in J Immunol. 1992;149:4116]. J Immunol. 1992;149:1531-1538.
16. Zhang M, Hung L, Gery I. Vasoactive intestinal peptide (VIP) exacerbates endotoxin-induced uveitis (EIU) in mice. Curr Eye Res. 2000;21:913-917.
17. Katayama T. The effect of vasoactive intestinal polypeptide (VIP) on ocular inflammation in rabbit ocular tissue [in Japanese]. Nippon Ganka Gakkai Zasshi. 1989;93:16-21.
18. Delgado M, Abad C, Martines C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563-568.